News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
262,885 Results
Type
Article (14018)
Company Profile (304)
Press Release (248563)
Section
Business (79405)
Career Advice (152)
Deals (13206)
Drug Delivery (34)
Drug Development (50360)
Employer Resources (31)
FDA (5691)
Job Trends (5120)
News (144209)
Policy (10018)
Tag
Academia (901)
Alliances (21578)
Alzheimer's disease (779)
Antibody-drug conjugate (ADC) (64)
Approvals (5679)
Artificial intelligence (80)
Bankruptcy (99)
Best Places to Work (4541)
Biotechnology (249)
Breast cancer (121)
Cancer (1001)
Cardiovascular disease (83)
Career advice (132)
CAR-T (82)
Cell therapy (241)
Clinical research (40336)
Collaboration (375)
Compensation (152)
COVID-19 (1013)
C-suite (99)
Cystic fibrosis (71)
Data (1047)
Diabetes (94)
Diagnostics (1217)
Earnings (29052)
Events (47380)
Executive appointments (302)
FDA (6117)
Funding (360)
Gene editing (70)
Gene therapy (179)
GLP-1 (327)
Government (1065)
Healthcare (6559)
Infectious disease (1054)
Inflammatory bowel disease (100)
IPO (7219)
Job creations (859)
Job search strategy (127)
Layoffs (191)
Legal (1377)
Lung cancer (146)
Lymphoma (63)
Manufacturing (91)
Medical device (2563)
Medtech (2564)
Mergers & acquisitions (6169)
Metabolic disorders (285)
Neuroscience (1059)
NextGen: Class of 2025 (2013)
Non-profit (850)
Northern California (1201)
Obesity (155)
Opinion (93)
Parkinson's disease (82)
Patents (68)
People (25224)
Phase I (14233)
Phase II (18753)
Phase III (11868)
Pipeline (447)
Postmarket research (851)
Preclinical (5979)
Radiopharmaceuticals (207)
Rare diseases (221)
Real estate (1411)
Regulatory (8348)
Research institute (932)
Series A (71)
Southern California (1080)
Startups (1967)
United States (9515)
Vaccines (174)
Weight loss (91)
Date
Today (71)
Last 7 days (220)
Last 30 days (1174)
Last 365 days (20412)
2025 (1037)
2024 (20574)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16225)
2018 (11738)
2017 (13746)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (17014)
Australia (2871)
California (2736)
Canada (869)
China (247)
Colorado (101)
Connecticut (116)
Europe (36596)
Florida (306)
Georgia (79)
Illinois (169)
Indiana (67)
Maryland (365)
Massachusetts (2172)
Minnesota (111)
New Jersey (675)
New York (751)
North Carolina (442)
Northern California (1201)
Ohio (88)
Pennsylvania (523)
South America (207)
Southern California (1080)
Texas (307)
Washington State (266)
262,885 Results for "aptevo therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
December 13, 2024
·
6 min read
BioForest
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
Aptevo Therapeutics Inc. today announced a presentation at The Essential Protein & Antibody Engineering Summit (PEGS) conference in Boston MA.
May 14, 2024
·
8 min read
BioForest
Aptevo Participating in the BIO International Convention 2024
Aptevo Therapeutics Inc. announced that the Company is participating in the BIO International Convention occurring June 3-6, 2024 in San Diego, CA.
June 3, 2024
·
4 min read
Deals
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules
Aptevo Therapeutics Inc. today announced that it has entered into securities purchase agreements with certain healthcare-focused and institutional investors to purchase (i) 5,339,806 shares of its common stock.
June 28, 2024
·
6 min read
Drug Development
Aptevo Therapeutics Provides Pipeline Update
Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced advancements in both clinical programs and one preclinical program.
April 10, 2024
·
12 min read
Press Releases
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
November 7, 2024
·
11 min read
Business
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended March 31, 2024 and provided a business update.
May 8, 2024
·
13 min read
Business
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
Aptevo Therapeutics Inc. today reported financial results for the year ended December 31, 2023 and provided a business update.
March 5, 2024
·
13 min read
Deals
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
Aptevo Therapeutics Inc. today announced the pricing of a public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock.
April 11, 2024
·
5 min read
Press Releases
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
November 27, 2024
·
7 min read
1 of 26,289
Next
